- Home
- ETON vs NATH Comparison
ETON vs NATH Comparison
Compare ETON & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- NATH
- Stock Information
- Founded
- ETON 2017
- NATH 1916
- Country
- ETON United States
- NATH United States
- Employees
- ETON N/A
- NATH N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- NATH Restaurants
- Sector
- ETON Health Care
- NATH Consumer Discretionary
- Exchange
- ETON Nasdaq
- NATH Nasdaq
- Market Cap
- ETON 329.8M
- NATH 330.5M
- IPO Year
- ETON 2018
- NATH N/A
- Fundamental
- Price
- ETON $14.68
- NATH $95.56
- Analyst Decision
- ETON Strong Buy
- NATH
- Analyst Count
- ETON 3
- NATH 0
- Target Price
- ETON $24.00
- NATH N/A
- AVG Volume (30 Days)
- ETON 270.3K
- NATH 13.7K
- Earning Date
- ETON 03-18-2025
- NATH 02-06-2025
- Dividend Yield
- ETON N/A
- NATH 2.09%
- EPS Growth
- ETON N/A
- NATH 24.88
- EPS
- ETON N/A
- NATH 5.80
- Revenue
- ETON $39,011,000.00
- NATH $146,386,000.00
- Revenue This Year
- ETON $22.19
- NATH N/A
- Revenue Next Year
- ETON $109.55
- NATH N/A
- P/E Ratio
- ETON N/A
- NATH $16.16
- Revenue Growth
- ETON 23.29
- NATH 6.83
- 52 Week Low
- ETON $3.03
- NATH $64.02
- 52 Week High
- ETON $18.41
- NATH $104.96
- Technical
- Relative Strength Index (RSI)
- ETON 47.04
- NATH 53.50
- Support Level
- ETON $14.28
- NATH $91.40
- Resistance Level
- ETON $15.73
- NATH $97.96
- Average True Range (ATR)
- ETON 1.02
- NATH 2.21
- MACD
- ETON 0.03
- NATH -1.15
- Stochastic Oscillator
- ETON 55.23
- NATH 31.73
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.